National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 10 of 1989)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, was established to provide a framework for the administration and funding of healthcare services within the country. One of the identified gaps in the original act was the need to regularly update and refine the list of substances covered under the Pharmaceutical Benefits Scheme (PBS), ensuring that the scheme remains relevant and effective. The Pharmaceutical Benefits Declaration under sub-section 85(2AA) No. PB10 of 1989, made by the Acting Principal Advisor, Health Care Access Division, Department of Community Services and Health, and Delegate of the Minister of State for Community Services and Health, aims to address this by removing certain drugs and medicinal preparations from the scope of Part VII of the National Health Act 1953, thereby improving the efficiency and accuracy of the PBS. The policy objective behind this declaration is to ensure that the Pharmaceutical Benefits Scheme only covers those drugs and preparations that meet the current health needs and standards of the Australian public.

Scope and Application

The Pharmaceutical Benefits Declaration under sub-section 85(2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations listed in the Schedule, thereby removing them from the coverage provided by Part VII of the Act. This legislative instrument is enacted at the Commonwealth level and affects entities and individuals involved in the supply and distribution of the specified drugs and medicinal preparations. The declared drugs, including Insulin, Biphasic Insulin Zinc Suspension (Amorphous), Vasopressin Tannate, Crystal Violet B.P. 1980, and Testosterone B.P., are no longer subject to the Pharmaceutical Benefits Scheme (PBS) as of 1 December 1989. This exclusion applies to all entities and individuals within the jurisdiction of the Commonwealth of Australia, impacting the health industry by altering the scope of pharmaceutical benefits available for these particular preparations. This Declaration does not explicitly mention any subordinate instruments extending or restricting its application, but it is understood that the National Health Act 1953 provides the legislative framework within which this and other related instruments operate.

Key Provisions

The Declaration, made under sub-section 85(2AA) of the National Health Act 1953, specifies that certain drugs and medicinal preparations will no longer be subject to Part VII of the Act, which deals with the Pharmaceutical Benefits Scheme (PBS). This means that the listed preparations will no longer receive the benefits provided by the PBS, such as subsidies for the cost of medications (section 2). The effective date of this change is set as 1 December 1989 (section 1). The listed drugs include Insulin, Biphasic Insulin Zinc Suspension (Amorphous), Vasopressin Tannate, Crystal Violet B.P. 1980, and Testosterone B.P., all of which are detailed in the Schedule to the Declaration. Under the National Health Act 1953, entities and individuals involved in the provision and distribution of these drugs and medicinal preparations are required to adhere to the provisions set forth in this Declaration. Specifically, they must ensure that the drugs and preparations mentioned in the Schedule are no longer claimed or administered as items covered under the PBS from the date of operation, 1 December 1989. This entails updating records, informing stakeholders, and potentially adjusting pricing or reimbursement processes to reflect the changes. Failure to comply with the provisions of this Declaration may lead to legal consequences. Although the specific penalties for non-compliance are not detailed within the text, breaches of the National Health Act 1953 generally attract fines and other penalties. For example, under section 120 of the Act, an individual may be fined up to 50 penalty units (currently AUD 5,300 as of 2023) for each offence, and a body corporate may be fined up to 250 penalty units (currently AUD 26,500 as of 2023) for each offence. Additionally, ongoing non-compliance could result in civil or criminal proceedings, further exacerbating the penalties imposed.